<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>North Bay Business Journal &#187; biotech</title>
	<atom:link href="http://www.northbaybusinessjournal.com/tag/biotech/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.northbaybusinessjournal.com</link>
	<description></description>
	<lastBuildDate>Thu, 09 Feb 2012 02:43:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Claret Medical raises $3 million, gets EU product approval</title>
		<link>http://www.northbaybusinessjournal.com/43043/claret-medical-raises-3-million-gets-eu-product-approval/</link>
		<comments>http://www.northbaybusinessjournal.com/43043/claret-medical-raises-3-million-gets-eu-product-approval/#comments</comments>
		<pubDate>Tue, 01 Nov 2011 01:17:01 +0000</pubDate>
		<dc:creator>Dan Verel, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Item]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Claret Medical Inc.]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[medical devices]]></category>
		<category><![CDATA[Santa Rosa]]></category>
		<category><![CDATA[Sonoma County]]></category>
		<category><![CDATA[startup]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=43043</guid>
		<description><![CDATA[SANTA ROSA -- Claret Medical, Inc., a recently formed Santa Rosa-based developer of methods designed to protect against brain embolism during vascular intervention and surgery, received European Union approval today for its Montage System. It's the second product approval this year. Claret has raised most of a $3.5 million round of private equity financing opened in late summer.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/43043/claret-medical-raises-3-million-gets-eu-product-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Eurofins Scientific adds DNA sequencing to Petaluma lab</title>
		<link>http://www.northbaybusinessjournal.com/36982/eurofins-scientific-adds-dna-sequencing-to-petaluma-lab/</link>
		<comments>http://www.northbaybusinessjournal.com/36982/eurofins-scientific-adds-dna-sequencing-to-petaluma-lab/#comments</comments>
		<pubDate>Mon, 25 Jul 2011 13:57:52 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Belgium]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Eurofins Scientific]]></category>
		<category><![CDATA[Eurofins Supplement Analysis Center]]></category>
		<category><![CDATA[gene sequencing]]></category>
		<category><![CDATA[Helaman Escobar]]></category>
		<category><![CDATA[North Bay Business Journal 7-25-2011]]></category>
		<category><![CDATA[Paul Brown]]></category>
		<category><![CDATA[Petaluma]]></category>
		<category><![CDATA[Sonoma County]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=36982</guid>
		<description><![CDATA[PETALUMA -- Eurofins Scientific has added a new DNA sequencing facility to its laboratory in Petaluma. Headquartered in Belgium, Eurofins is an international provider of bioanalysis services and products for academic and industrial laboratories worldwide. It’s main U.S. genetic sequencing center is in Huntsville, Ala.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/36982/eurofins-scientific-adds-dna-sequencing-to-petaluma-lab/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioMarin begins phase 3 drug trial in Europe</title>
		<link>http://www.northbaybusinessjournal.com/35049/biomarin-begins-phase-3-drug-trial-in-europe/</link>
		<comments>http://www.northbaybusinessjournal.com/35049/biomarin-begins-phase-3-drug-trial-in-europe/#comments</comments>
		<pubDate>Tue, 07 Jun 2011 19:30:47 +0000</pubDate>
		<dc:creator>Dan Verel, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[Marin County]]></category>
		<category><![CDATA[Novato]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=35049</guid>
		<description><![CDATA[NOVATO -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the start of phase 3 trial in Europe of a treatment for a rare immune system disease, Lambert-Eaton Myasthenic Syndrome, or LEMS.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/35049/biomarin-begins-phase-3-drug-trial-in-europe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Retired BioMarin drug researcher launches Ultragenyx</title>
		<link>http://www.northbaybusinessjournal.com/32803/retired-biomarin-drug-researcher-launches-ultragenyx/</link>
		<comments>http://www.northbaybusinessjournal.com/32803/retired-biomarin-drug-researcher-launches-ultragenyx/#comments</comments>
		<pubDate>Mon, 18 Apr 2011 13:01:17 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[Aldurazyme]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Emil Kakkis]]></category>
		<category><![CDATA[Genzyme]]></category>
		<category><![CDATA[Kakkis EveryLife Foundation]]></category>
		<category><![CDATA[Kuvan]]></category>
		<category><![CDATA[Mucopolysaccharidosis - MPS]]></category>
		<category><![CDATA[Naglazyme]]></category>
		<category><![CDATA[Novato]]></category>
		<category><![CDATA[orphan drugs]]></category>
		<category><![CDATA[startup]]></category>
		<category><![CDATA[Ultragenyx Pharmaceutical]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=32803</guid>
		<description><![CDATA[NOVATO -- A former BioMarin Pharmaceutical Inc. drug developer has started a new company to create therapies for rare diseases.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/32803/retired-biomarin-drug-researcher-launches-ultragenyx/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oculus gets $1 million to develop Microcyn</title>
		<link>http://www.northbaybusinessjournal.com/29894/oculus-gets-1-million-to-develop-microcyn/</link>
		<comments>http://www.northbaybusinessjournal.com/29894/oculus-gets-1-million-to-develop-microcyn/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 01:13:18 +0000</pubDate>
		<dc:creator>Business Journal Staff Report</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[Amneal Enterprises]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[Microcyn]]></category>
		<category><![CDATA[Oculus Innovative Sciences]]></category>
		<category><![CDATA[Petaluma]]></category>
		<category><![CDATA[Sonoma County]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=29894</guid>
		<description><![CDATA[PETALUMA -- Amneal Enterprises, an affiliation of independent pharmaceutical marketing, discovery and development companies, and Petaluma-based Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced that Amneal alliance members have formed a broad multiyear collaboration with Oculus to realize the development and commercial potential of Oculus' Microcyn technology.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/29894/oculus-gets-1-million-to-develop-microcyn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioMarin starts pivotal clinical trial for GALNS treatment</title>
		<link>http://www.northbaybusinessjournal.com/29268/biomarin-starts-pivotal-clinical-trial-for-galns-treatment/</link>
		<comments>http://www.northbaybusinessjournal.com/29268/biomarin-starts-pivotal-clinical-trial-for-galns-treatment/#comments</comments>
		<pubDate>Tue, 01 Feb 2011 23:04:20 +0000</pubDate>
		<dc:creator>Business Journal Staff Report</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[enzyme replacement therapies]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marin County]]></category>
		<category><![CDATA[Mucopolysaccharidosis type IVA - MPS IVA]]></category>
		<category><![CDATA[Novato]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=29268</guid>
		<description><![CDATA[NOVATO -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it started a phase 3 trial for N-acetylgalactosamine 6-sulfatase, named GALNS or BMN 110. It's intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis type IVA, or MPS IVA, also called Morquio A syndrome.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/29268/biomarin-starts-pivotal-clinical-trial-for-galns-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Osseon names CFO</title>
		<link>http://www.northbaybusinessjournal.com/27811/osseon-names-cfo/</link>
		<comments>http://www.northbaybusinessjournal.com/27811/osseon-names-cfo/#comments</comments>
		<pubDate>Sat, 11 Dec 2010 02:17:20 +0000</pubDate>
		<dc:creator>Business Journal Staff Report</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Osseon Therapeutics]]></category>
		<category><![CDATA[Petaluma]]></category>
		<category><![CDATA[Sonoma County]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=27811</guid>
		<description><![CDATA[SANTA ROSA – Osseon Therapeutics named Gary Coughlen, CPA, as chief financial officer. Osseon specializes in alternative minimally invasive treatments for degenerative bone and joint disease.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/27811/osseon-names-cfo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oculus boosts revenue 47 percent, narrows loss</title>
		<link>http://www.northbaybusinessjournal.com/26627/oculus-boosts-revenue-47-percent-narrows-loss/</link>
		<comments>http://www.northbaybusinessjournal.com/26627/oculus-boosts-revenue-47-percent-narrows-loss/#comments</comments>
		<pubDate>Thu, 04 Nov 2010 23:50:17 +0000</pubDate>
		<dc:creator>Business Journal Staff Report</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[earnings]]></category>
		<category><![CDATA[Oculus]]></category>
		<category><![CDATA[Petaluma]]></category>
		<category><![CDATA[Sonoma County]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=26627</guid>
		<description><![CDATA[PETALUMA -- Oculus Innovative Systems Inc. (Nasdaq: OCLS), a commercial developer of topical disinfectants and treatments, today reported second-quarter revenue increased 47 percent to $2.5 million, and net loss improved to $1.1 million in the same period.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/26627/oculus-boosts-revenue-47-percent-narrows-loss/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioMarin posts rise in profit, revenue</title>
		<link>http://www.northbaybusinessjournal.com/26471/biomarin-posts-rise-in-profit-revenue/</link>
		<comments>http://www.northbaybusinessjournal.com/26471/biomarin-posts-rise-in-profit-revenue/#comments</comments>
		<pubDate>Thu, 28 Oct 2010 21:53:15 +0000</pubDate>
		<dc:creator>Business Journal Staff Report</dc:creator>
				<category><![CDATA[Employment]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[earnings]]></category>
		<category><![CDATA[Marin County]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=26471</guid>
		<description><![CDATA[NOVATO – BioMarin Pharmaceutical posted $217.3 million in profit for the third quarter.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/26471/biomarin-posts-rise-in-profit-revenue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TriVascular stent OK&#8217;d for Europe</title>
		<link>http://www.northbaybusinessjournal.com/25122/trivascular-stent-okd-for-europe/</link>
		<comments>http://www.northbaybusinessjournal.com/25122/trivascular-stent-okd-for-europe/#comments</comments>
		<pubDate>Tue, 21 Sep 2010 23:02:45 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Michael Chobotov]]></category>
		<category><![CDATA[Sonoma County]]></category>
		<category><![CDATA[TriVascular]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=25122</guid>
		<description><![CDATA[SANTA ROSA – TriVascular Inc. gained European approval for its Ovation Abdominal Stent Graft, the company announced today. It’s the first TriVascular product to be approved for the European market.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/25122/trivascular-stent-okd-for-europe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Medtronic stent OK&#8217;d for U.S.</title>
		<link>http://www.northbaybusinessjournal.com/25110/medtronic-stent-okd-for-u-s/</link>
		<comments>http://www.northbaybusinessjournal.com/25110/medtronic-stent-okd-for-u-s/#comments</comments>
		<pubDate>Mon, 20 Sep 2010 21:49:28 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Medtronic CardioVascular]]></category>
		<category><![CDATA[Santa Rosa]]></category>
		<category><![CDATA[Sonoma County]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=25110</guid>
		<description><![CDATA[SANTA ROSA -- Medtronic Inc. (NYSE: MDT) received U.S. Food and Drug Administration approval for its Integrity Coronary Stent System, the company announced today.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/25110/medtronic-stent-okd-for-u-s/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Buck, BioMarin in joint research effort</title>
		<link>http://www.northbaybusinessjournal.com/25042/buck-biomarin-in-joint-research-effort/</link>
		<comments>http://www.northbaybusinessjournal.com/25042/buck-biomarin-in-joint-research-effort/#comments</comments>
		<pubDate>Mon, 20 Sep 2010 11:51:40 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Position]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Dale Bredesen]]></category>
		<category><![CDATA[Familial Alzheimer’s]]></category>
		<category><![CDATA[Gordon Vehar]]></category>
		<category><![CDATA[Marin County]]></category>
		<category><![CDATA[Novato]]></category>
		<category><![CDATA[The Buck Institute on Age Research]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=25042</guid>
		<description><![CDATA[NOVATO – The Buck Institute for Age Research and BioMarin Pharmaceutical are collaborating on what could be a breakthrough therapy for a most feared disease.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/25042/buck-biomarin-in-joint-research-effort/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioMarin acquires ZyStor in $115 million deal</title>
		<link>http://www.northbaybusinessjournal.com/24076/biomarin-acquires-zystor-in-115-million-deal/</link>
		<comments>http://www.northbaybusinessjournal.com/24076/biomarin-acquires-zystor-in-115-million-deal/#comments</comments>
		<pubDate>Wed, 18 Aug 2010 00:40:08 +0000</pubDate>
		<dc:creator>Business Journal Staff Report</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[lysosomal storage disorders]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marin County]]></category>
		<category><![CDATA[mergers and acquisitions]]></category>
		<category><![CDATA[Novato]]></category>
		<category><![CDATA[Pompe disease]]></category>
		<category><![CDATA[ZyStor Therapeutics]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=24076</guid>
		<description><![CDATA[NOVATO --  BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today said it acquired privately held biotechnology company ZyStor Therapeutics Inc. in a deal valued at $115 million.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/24076/biomarin-acquires-zystor-in-115-million-deal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Benicia exploring ways to attract technology companies</title>
		<link>http://www.northbaybusinessjournal.com/23930/benicia-exploring-ways-to-attract-technology-companies/</link>
		<comments>http://www.northbaybusinessjournal.com/23930/benicia-exploring-ways-to-attract-technology-companies/#comments</comments>
		<pubDate>Mon, 16 Aug 2010 09:10:57 +0000</pubDate>
		<dc:creator>Dan Verel, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Local Government]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Amalia Lorentz]]></category>
		<category><![CDATA[Benicia]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[CEQA]]></category>
		<category><![CDATA[Mark Rhoades]]></category>
		<category><![CDATA[Solano County]]></category>
		<category><![CDATA[viveria]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=23930</guid>
		<description><![CDATA[BENICIA — As a means of attracting more jobs to the city, Benicia is considering adjusting zoning and land-use laws that would permit more tech and development companies to occupy about one third of the city’s land area, including all of its industrial park.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/23930/benicia-exploring-ways-to-attract-technology-companies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TriVascular obtains new $60 million infusion</title>
		<link>http://www.northbaybusinessjournal.com/23033/trivascular-obtains-new-60-million-infusion/</link>
		<comments>http://www.northbaybusinessjournal.com/23033/trivascular-obtains-new-60-million-infusion/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 22:17:34 +0000</pubDate>
		<dc:creator>Business Journal Staff Report</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Employment]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[Pinnacle Ventures]]></category>
		<category><![CDATA[Santa Rosa]]></category>
		<category><![CDATA[Sonoma County]]></category>
		<category><![CDATA[TriVascular]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=23033</guid>
		<description><![CDATA[SANTA ROSA -- TriVascular of Santa Rosa, California, announced today the close of $60 million in funding, comprised of a Series C equity financing and growth capital venture debt.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/23033/trivascular-obtains-new-60-million-infusion/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TriVascular in first U.S. clinical trial; will add 100 jobs</title>
		<link>http://www.northbaybusinessjournal.com/21073/trivascular-in-first-u-s-clinical-trial-will-add-100-jobs/</link>
		<comments>http://www.northbaybusinessjournal.com/21073/trivascular-in-first-u-s-clinical-trial-will-add-100-jobs/#comments</comments>
		<pubDate>Wed, 05 May 2010 20:02:07 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[medical devices]]></category>
		<category><![CDATA[Mike Chobotov]]></category>
		<category><![CDATA[Santa Rosa]]></category>
		<category><![CDATA[Sonoma County]]></category>
		<category><![CDATA[TriVascular]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=21073</guid>
		<description><![CDATA[SANTA ROSA -- TriVascular announced today the first U.S. clinical study of its abdominal stent graft, a device that promises to significantly increase the pool of candidates for minimally invasive treatment of aortic aneurisms.

]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/21073/trivascular-in-first-u-s-clinical-trial-will-add-100-jobs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioMarin launches drug in Europe</title>
		<link>http://www.northbaybusinessjournal.com/20406/biomarin-launches-drug-in-europe/</link>
		<comments>http://www.northbaybusinessjournal.com/20406/biomarin-launches-drug-in-europe/#comments</comments>
		<pubDate>Mon, 19 Apr 2010 20:28:48 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Marin County]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=20406</guid>
		<description><![CDATA[NOVATO -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Firdapse is now commercially available in Germany and the UK.

 

For the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome, Firdapse is expected to be in all major European markets by the end of 2010. ]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/20406/biomarin-launches-drug-in-europe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TriVascular trials progress in Europe</title>
		<link>http://www.northbaybusinessjournal.com/19674/trivascular-trials-progress-in-europe/</link>
		<comments>http://www.northbaybusinessjournal.com/19674/trivascular-trials-progress-in-europe/#comments</comments>
		<pubDate>Mon, 29 Mar 2010 11:54:30 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Position]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[Cook Medical]]></category>
		<category><![CDATA[EVAR]]></category>
		<category><![CDATA[Gore Medical]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[medical devices]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[Michael Chobotov]]></category>
		<category><![CDATA[Ovation abdominal stent graft]]></category>
		<category><![CDATA[TriVascular]]></category>
		<category><![CDATA[Vivek Jayaraman]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=19674</guid>
		<description><![CDATA[SANTA ROSA -- TriVascular's abdominal stent graft is showing solid results in European clinical trials, well on its way to holding a leading position in a predicted $2 billion global market.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/19674/trivascular-trials-progress-in-europe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioMarin acquires LEAD Therapeutics</title>
		<link>http://www.northbaybusinessjournal.com/18093/biomarin-acquires-lead-therapeutics/</link>
		<comments>http://www.northbaybusinessjournal.com/18093/biomarin-acquires-lead-therapeutics/#comments</comments>
		<pubDate>Fri, 05 Feb 2010 21:54:05 +0000</pubDate>
		<dc:creator>Business Journal Staff Report</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[LEAD Therapeutics]]></category>
		<category><![CDATA[Marin County]]></category>
		<category><![CDATA[mergers and acquisitions]]></category>
		<category><![CDATA[Novato]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=18093</guid>
		<description><![CDATA[NOVATO -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said it plans to acquire LEAD Therapeutics Inc. of San Bruno in a stock deal worth $18 million up front and up to $97 million as the drug is submitted for government review and later released.

]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/18093/biomarin-acquires-lead-therapeutics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TriVascular gets $30 million Series B</title>
		<link>http://www.northbaybusinessjournal.com/16766/trivascular-gets-30-million-series-b/</link>
		<comments>http://www.northbaybusinessjournal.com/16766/trivascular-gets-30-million-series-b/#comments</comments>
		<pubDate>Mon, 16 Nov 2009 20:45:40 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Position]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Boston Scientific]]></category>
		<category><![CDATA[Delphi Ventures]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[Kearny Venture Parnters]]></category>
		<category><![CDATA[MPM Capital]]></category>
		<category><![CDATA[New Enterprise Associates]]></category>
		<category><![CDATA[TriVascular]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=16766</guid>
		<description><![CDATA[SANTA ROSA --TriVascular Inc. announced today it has raised $30 million in a Series B offering. The funds will take the maker of abdominal and thoracic stent graft systems into clinical testing.

The Series B financing is a continuation of Series A funding of $65 million in 2008 from  investors New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/16766/trivascular-gets-30-million-series-b/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioMarin acquires Huxley Pharmaceuticals</title>
		<link>http://www.northbaybusinessjournal.com/16230/biomarin-acquires-huxley-pharmaceuticals/</link>
		<comments>http://www.northbaybusinessjournal.com/16230/biomarin-acquires-huxley-pharmaceuticals/#comments</comments>
		<pubDate>Tue, 27 Oct 2009 21:40:07 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Huxley Pharmaceuticals]]></category>
		<category><![CDATA[Marin County]]></category>
		<category><![CDATA[Novato]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=16230</guid>
		<description><![CDATA[NOVATO -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has acquired Huxley Pharmaceuticals inc. for $15 million, with further payments to Huxley shareholders of up to $50 million if certain milestones are reached.

]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/16230/biomarin-acquires-huxley-pharmaceuticals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioMarin, doubling manufacturing capacity, sees quarterly earnings decline</title>
		<link>http://www.northbaybusinessjournal.com/12893/biomarin-doubling-manufacturing-capacity-sees-quarterly-earnings-decline/</link>
		<comments>http://www.northbaybusinessjournal.com/12893/biomarin-doubling-manufacturing-capacity-sees-quarterly-earnings-decline/#comments</comments>
		<pubDate>Thu, 30 Jul 2009 22:37:55 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Employment]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[BioMarin Pharmaceutical]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marin County]]></category>
		<category><![CDATA[Novato]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=12893</guid>
		<description><![CDATA[NOVATO -- BioMarin Pharmaceuticals Inc.  (NASDAQ: BMRN) said today investments made to double manufacturing capacity caused it to post lower second-quarter profit as operating expenses jumped 32 percent during the quarter.

]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/12893/biomarin-doubling-manufacturing-capacity-sees-quarterly-earnings-decline/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Raptor Pharmaceutical to merge with TorreyPines Therapeutics</title>
		<link>http://www.northbaybusinessjournal.com/12662/raptor-pharmaceutical-to-merge-with-torreypines-therapeutics/</link>
		<comments>http://www.northbaybusinessjournal.com/12662/raptor-pharmaceutical-to-merge-with-torreypines-therapeutics/#comments</comments>
		<pubDate>Tue, 28 Jul 2009 20:13:40 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Position]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Marin County]]></category>
		<category><![CDATA[Nasdaq]]></category>
		<category><![CDATA[Novato]]></category>
		<category><![CDATA[Raptor Pharmaceutical]]></category>
		<category><![CDATA[TorreyPines Therapeutics]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=12662</guid>
		<description><![CDATA[NOVATO - Raptor Pharmaceuticals Corp. has agreed to merge with TorreyPines Therapeutics Inc. (Nasdaq: TPTX), giving the Novato developer of drug-targeting platforms and mid- to late-stage clinical development candidates a listing on Nasdaq. The merged company will most likely retain the Raptor name, executive team and Novato location.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/12662/raptor-pharmaceutical-to-merge-with-torreypines-therapeutics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Medtronic CardioVascular receives FDA&#8217;s &#8216;humanitarian&#8217; approval for heart valve</title>
		<link>http://www.northbaybusinessjournal.com/12280/medtronic-cardiovascular-receives-fdas-humanitarian-approval-for-heart-valve/</link>
		<comments>http://www.northbaybusinessjournal.com/12280/medtronic-cardiovascular-receives-fdas-humanitarian-approval-for-heart-valve/#comments</comments>
		<pubDate>Wed, 22 Jul 2009 23:09:42 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Position]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[Santa Rosa]]></category>
		<category><![CDATA[Sonoma County]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=12280</guid>
		<description><![CDATA[SANTA ROSA – Santa Rosa-based Medtronic CardioVascular received unanimous approval today from an FDA panel to grant "Humanitarian Use Device" status to its Melody Transcatheter Pulmonary Valve, a decision that will expedite FDA approval of the device.]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/12280/medtronic-cardiovascular-receives-fdas-humanitarian-approval-for-heart-valve/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Novato&#8217;s Buck Institute gets $970,000 in stimulus</title>
		<link>http://www.northbaybusinessjournal.com/11907/novatos-buck-institute-gets-stimulus/</link>
		<comments>http://www.northbaybusinessjournal.com/11907/novatos-buck-institute-gets-stimulus/#comments</comments>
		<pubDate>Thu, 16 Jul 2009 22:21:24 +0000</pubDate>
		<dc:creator>Loralee Stevens, Business Journal Staff Reporter</dc:creator>
				<category><![CDATA[Breaking News]]></category>
		<category><![CDATA[Education]]></category>
		<category><![CDATA[Health Care and Senior Living]]></category>
		<category><![CDATA[Position]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Top News Stories]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Novato]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[The Buck Institute on Age Research]]></category>

		<guid isPermaLink="false">http://www.northbaybusinessjournal.com/?p=11907</guid>
		<description><![CDATA[NOVATO, July 16, 2009 &#8212; The Buck Institute for Age Research has been awarded $970,000 from the National Institutes of Health as part of the American Recovery and Reinvestment Act stimulus funding, the first installment, it hopes, of more awards. The two-year grant will fund research on the function of newborn neurons in aged brains [...]]]></description>
		<wfw:commentRss>http://www.northbaybusinessjournal.com/11907/novatos-buck-institute-gets-stimulus/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
	</channel>
</rss>

